In this Review:
NF1 and RASopathy gene mutations in melanoma
The genetic evolution of melanoma from precursor lesions
Preliminary clinical safety, tolerability and activity of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600 metastatic melanoma
Aging and melanoma: a Wnt-er of discontent
Efficacy and safety of nivolumab monotherapy in the treatment of advanced mucosal melanoma
Baseline and postbaseline characteristics associated with treatment benefit across dabrafenib and trametinib registration pooled data
DERMA, a double-blind, randomized, placebo-controlled phase III study to assess the efficacy of MAGE-A3 cancer immunotherapeutic adjuvant therapy
KEYNOTE-029: Pembrolizumab + low-dose ipilimumab for advanced melanoma
Improved overall survival with cobimetinib and vemurafenib in advanced BRAF-mutated melanoma
Preliminary data from a phase 1/2 study of epacadostat (INCB024360) with pembrolizumab
Please login below to download this issue (PDF)